These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29771880)

  • 21. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs.
    Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH
    Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
    Chang CK; Cheng CK; Peng CH
    Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ranibizumab in diabetic macular edema. Evaluation of functional and morphological aspects].
    Reznicek L; Cserhati S; Liegl R; Seidensticker F; Haritoglou C; Wolf A; Kampik A; Ulbig MW; Neubauer A; Kernt M
    Ophthalmologe; 2013 Jul; 110(7):645-53. PubMed ID: 23436196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.
    Jakobsen NS; Larsen DA; Bek T
    Acta Ophthalmol; 2018 Nov; 96(7):744-748. PubMed ID: 29687595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
    Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
    BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.
    Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG
    Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
    Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
    Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
    Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
    Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
    Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
    Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.